Stay updated on Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.

Latest updates to the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page
- Check4 days agoChange DetectedRevision tag updated to v3.5.2.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe study’s Conditions list now includes squamous cell carcinoma of the head and neck and nasal cavity/paranasal sinus carcinoma.SummaryDifference0.1%

- Check32 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check40 days agoChange Detected- Revision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check54 days agoChange DetectedHypopharynx cancer and Oropharynx cancer were added to the Conditions list, and a Genetic and Rare Diseases Information Center resource was added under Resources.SummaryDifference0.2%

- Check68 days agoChange DetectedAdded site revision note: Revision v3.4.2. Removed older notices (Revision v3.4.1) and the funding-status message; no trial data or core page content was altered.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.